BioMedNewsBreaks

ThursdayJan 28, 2021 10:53 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Drug Formulation Strategy, 2021 Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its drug formulation and delivery business strategy and milestones for 2021. According to the update, XPhyto, as a bioscience accelerator at the leading-edge of the life science industry, targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. Regarding XPhyto's drug formulation business, the company has set the strategy and milestones for 2021 of its wholly owned German subsidiary, Vektor Pharma TF GmbH. Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental…

Continue Reading

ThursdayJan 28, 2021 10:41 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the announcement, the company noted that the Phase 2b OPTION 2 trial extension arm is dosing patients at sites in the United States and Europe; patients in this study previously participated in arms of the OPTION 2 trial. The ultimate objective of the MS1819 program…

Continue Reading

WednesdayJan 27, 2021 3:11 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth's multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health platforms. The move also brings together complementary companies with industry-leading consumer engagement and clinical outcomes. In addition, DRIO has entered into definitive agreements with a group of health-care institutional investors to raise $70 million through a private…

Continue Reading

WednesdayJan 27, 2021 1:33 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company overview, including a synopsis of its diabetes gene therapy and details on the recent progress made on GNPX’s upcoming clinical trials for the treatment of non-small cell lung cancer. Following the conference, a replay of GNPX’s presentation will be available on the company’s website for…

Continue Reading

WednesdayJan 27, 2021 12:17 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for Predictive Oncology will total approximately $4.1 million, before fees and other offering expenses are deducted. POAI anticipates using net proceeds from the offering for working capital projects and purposes.  The company also announced a concurrent…

Continue Reading

TuesdayJan 26, 2021 11:36 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Addition of Two Clinical Trial Sites for MS1819 Phase 2b OPTION 2 Extension Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has added two clinical trial sites for the extension arm of its MS1819 Phase 2b OPTION 2 study. The study is investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). The additional sites were added in Poland; Europe was selected to reduce potential patient-enrollment delays caused by the COVID-19 pandemic. The two sites in Poland and the active clinical trial sites in the United States have already begun enrolling patients. AzurRX expects  topline data to be available…

Continue Reading

FridayJan 22, 2021 12:49 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees…

Continue Reading

ThursdayJan 21, 2021 11:40 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces Plans to Develop Micro Brain E-Tattoo Device for Growing Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has begun development of a brain E-Tattoo device. The company announced that the innovative product will feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The electrodes will connect to the micro EEG, which will be located behind the ear and which processes signals from the sensors and transfers the data to a cloud application. The proprietary offering is designed to provide continuous monitoring for data collection in patients with epilepsy and Alzheimer’s as well as patients who have suffered a stroke or…

Continue Reading

ThursdayJan 21, 2021 11:00 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Beginning of MS1819 Extension Study with Initial Dosing of Two Patients

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The OPTION 2 extension phase design, which was recently announced by AzurRx, is designed to evaluate patients…

Continue Reading

ThursdayJan 21, 2021 10:28 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light on recent advancements concerning its upcoming clinical trials for the treatment of non-small cell lung cancer. The company will present at 12:25 PM EST on Thursday, January 28th. The presentation will be available for replay on the company’s website and www.MoneyShow.com. To register for the…

Continue Reading